Jove
Visualize
Contact Us

Related Experiment Videos

Prevention of bronchiolitis.

C R Pringle1

  • 1Biological Sciences Department, University of Warwick, Coventry, CV4 7AL, UK. cp@dna.bio.warwick.ac.uk

Paediatric Respiratory Reviews
|January 18, 2003
PubMed
Summary

Preventing human respiratory syncytial virus (HRSV) infection in infants remains challenging. Current strategies focus on passive immunization for high-risk infants, as effective vaccines and antivirals are still unavailable.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The composition and structure of rhabdoviruses.

Revue scientifique et technique (International Office of Epizootics)·2020
Same author

Temperature-sensitive mutant vaccines.

Methods in molecular medicine·2011
Same author

Optimising non-viral gene delivery in a tumour spheroid model.

The journal of gene medicine·2006
Same author

Abbreviations for bacterial and fungal virus species names.

Archives of virology·2000
Same author

Abbreviations for invertebrate virus species names.

Archives of virology·1999
Same author

Virus taxonomy at the XIth International Congress of Virology, Sydney, Australia, 1999.

Archives of virology·1999
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Pediatrics
  • Virology
  • Immunology

Background:

  • Human respiratory syncytial virus (HRSV) causes significant infant bronchiolitis.
  • Past vaccine trials, including formalin-inactivated vaccines, showed adverse effects like disease potentiation.
  • Understanding HRSV immunopathology is crucial for developing safe and effective interventions.

Purpose of the Study:

  • To review the current status and future prospects for controlling HRSV infection and bronchiolitis in infants.
  • To assess the efficacy and limitations of existing and emerging HRSV countermeasures.
  • To highlight the shift towards passive immunization strategies.

Main Methods:

  • Literature review of HRSV research, vaccine development, and immunoprophylaxis.
  • Analysis of historical vaccine trials and their outcomes.
  • Evaluation of current passive immunization agents and antiviral research.

Main Results:

  • No approved active vaccines (subunit, live attenuated) for HRSV are currently available.
  • Passive immunization with concentrated human immune globulin (RespiGam) and Palivizumab (monoclonal antibody) is approved.
  • These passive treatments are recommended primarily for high-risk infants due to cost-effectiveness.
  • An effective antiviral therapy for HRSV infection is still lacking.

Conclusions:

  • Effective containment of HRSV infection in infants requires further research and development.
  • Passive immunization offers a viable, albeit limited, option for vulnerable infant populations.
  • Future efforts may focus on novel vaccine platforms and targeted antiviral therapies.

Related Experiment Videos